Ablation Device Market Scope And Analysis

  • Report Code : TIPRE00003095
  • Category : Life Sciences
  • No. of Pages : 185
Buy Now

Ablation Device Market Analysis, Trends, and Scope 2021 to 2022

Buy Now


Ablation Device Market Report Scope

Report Attribute Details
Market size in 2022 US$ 8,325.32 Million
Market Size by 2030 US$ 16,020.33 Million
Global CAGR (2022 - 2030) 8.5 %
Historical Data 2020-2022
Forecast period 2022-2030
Segments Covered By Device
  • Radiofrequency Devices
  • Laser/Light Ablation
  • Ultrasound Devices
  • Cryoablation Devices
  • Other Devices
By Application
  • Cancer Treatment
  • Cardiovascular Disease Treatment
  • Ophthalmologic Treatment
  • Gynecological Treatment
  • Urological Treatment
  • Cosmetic Surgery
By End-User
  • Hospitals and Clinics
  • Ambulatory Surgical Centers
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • Abbott Laboratories
  • AngioDynamics Inc
  • AtriCure Inc
  • Biotronik
  • Boston Scientific Corporation
  • Conmed Corporation
  • Johnson and Johnson
  • Medtronic PLC
  • Olympus Corporation
  • Industry Developments and Future Opportunities: 

    Technological advancements in the field of ablation have significantly improved the effectiveness and safety of procedures. Newer ablation devices incorporate advanced technologies such as radiofrequency, microwave, cryoablation, and laser, enabling precise tissue destruction while minimizing damage to surrounding healthy tissues. These advancements have increased the success rates and expanded the scope of ablation procedures, driving market growth. Various initiatives taken by key players operating in the global ablation device market are listed below:

    A few of the recent developments in the global ablation device market are mentioned below:

    1. In May 2023, Abbott received US Food and Drug Administration (FDA) approval for its TactiFlex Ablation Catheter (Sensor Enabled), which became the world's first ablation catheter featuring a flexible tip and contact force technology.
    2. In February 2023, the NovaSure V5 global endometrial ablation (GEA) device of Hologic Inc. was approved for medical usage in Canada and Europe. This innovative version incorporates enhanced features for the treatment of a broad range of cervical and uterine anatomies.
    3. In November 2021, Medtronic India launched the Arctic Front Cardiac Cryoablation Catheter System for atrial fibrillation (AF) treatment in the country. The system is used to perform minimally invasive cryoballoon catheter ablation, one of the therapeutic modalities used to manage AF.
    4. In January 2021, Medtronic plc received FDA approval for the DiamondTemp Ablation (DTA) system, which is indicated for treating patients with recurrent, symptomatic paroxysmal AF, particularly for those who have been unresponsive to conventional drugs. The DTA is the first FDA-approved, temperature-controlled, irrigated radiofrequency (RF) ablation system with diamonds, which is currently available to deliver ablations.
    5. In December 2020, Acutus Medical launched the AcQBlate Force Sensing Ablation System in Europe. The product was launched after securing the CE Mark for the AcQBlate Force ablation catheter and the Qubic Force Sensing Module. AcQBlate Force incorporated by this ablation system is the only commercially available gold-tipped, irrigated, force-sensing radiofrequency ablation catheter on the market. The system also integrates two state-of-the-art components made available through Acutus Medical’s international alliance with BIOTRONIK—the Qubic RF and the Qiona Irrigation Pump.
    6. In November 2020, Abbott announced the launch of the IonicRF Generator, a device cleared by the FDA to deliver a nonsurgical, minimally invasive treatment for the management of pain in the nervous system. This RF ablation device uses heat to target specific nerves and block pain signals from reaching the brain. The device is currently approved for sale in the US and Europe.

    Competitive Landscape and Key Companies:

    Abbott Laboratories, AngioDynamics Inc, AtriCure Inc, Biotronik, Boston Scientific Corporation, Conmed Corporation, Johnson and Johnson, Medtronic PLC, Olympus Corporation, and Smith & Nephew PLC are among the prominent players operating in the ablation device market. These companies focus on new technologies, advancements in existing products, and geographic expansions to meet the growing consumer demand worldwide and increase their product range in specialty portfolios.